Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Supreme Court Decisions | 2 | 2023 | 3 | 1.910 |
Why?
|
| Schools, Medical | 3 | 2021 | 192 | 1.120 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2006 | 44 | 1.050 |
Why?
|
| Legislation, Medical | 1 | 2023 | 1 | 0.960 |
Why?
|
| Public Policy | 1 | 2023 | 31 | 0.940 |
Why?
|
| Medicine | 1 | 2023 | 31 | 0.930 |
Why?
|
| Physicians | 2 | 2023 | 148 | 0.870 |
Why?
|
| Minority Groups | 4 | 2023 | 537 | 0.850 |
Why?
|
| Cultural Diversity | 1 | 2021 | 158 | 0.720 |
Why?
|
| Students, Medical | 1 | 2021 | 121 | 0.690 |
Why?
|
| Milk, Human | 1 | 2018 | 29 | 0.660 |
Why?
|
| Health Status Disparities | 3 | 2018 | 583 | 0.620 |
Why?
|
| Breast Feeding | 1 | 2018 | 105 | 0.610 |
Why?
|
| Postmenopause | 2 | 2005 | 125 | 0.490 |
Why?
|
| Estrogens | 2 | 2013 | 190 | 0.470 |
Why?
|
| Menopause | 4 | 2007 | 54 | 0.430 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 94 | 0.410 |
Why?
|
| Kidney Diseases | 1 | 2013 | 159 | 0.390 |
Why?
|
| Vitamin D | 1 | 2013 | 176 | 0.390 |
Why?
|
| Cardiovascular Diseases | 3 | 2013 | 628 | 0.350 |
Why?
|
| Humans | 24 | 2023 | 34853 | 0.350 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2006 | 11 | 0.340 |
Why?
|
| Estradiol | 3 | 2007 | 244 | 0.300 |
Why?
|
| Contraceptive Agents, Female | 1 | 2006 | 23 | 0.280 |
Why?
|
| Bone Density | 1 | 2006 | 76 | 0.280 |
Why?
|
| Medroxyprogesterone | 2 | 2002 | 2 | 0.270 |
Why?
|
| Ethinyl Estradiol | 2 | 2002 | 9 | 0.270 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2002 | 11 | 0.270 |
Why?
|
| Complementary Therapies | 1 | 2005 | 45 | 0.270 |
Why?
|
| Hot Flashes | 4 | 2005 | 7 | 0.250 |
Why?
|
| Women's Health | 1 | 2005 | 135 | 0.240 |
Why?
|
| Exercise Therapy | 1 | 2004 | 64 | 0.240 |
Why?
|
| Female | 19 | 2021 | 19873 | 0.240 |
Why?
|
| United States | 5 | 2021 | 3894 | 0.230 |
Why?
|
| Momordica | 1 | 2022 | 14 | 0.220 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 531 | 0.210 |
Why?
|
| HIV Seropositivity | 1 | 2022 | 182 | 0.200 |
Why?
|
| Endometriosis | 1 | 2002 | 69 | 0.190 |
Why?
|
| History, 20th Century | 1 | 2021 | 110 | 0.190 |
Why?
|
| Educational Measurement | 1 | 2021 | 80 | 0.190 |
Why?
|
| Oocyte Donation | 1 | 2010 | 1 | 0.190 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 50 | 0.180 |
Why?
|
| Catechin | 2 | 2010 | 30 | 0.180 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 303 | 0.180 |
Why?
|
| Educational Status | 1 | 2021 | 295 | 0.180 |
Why?
|
| Antisickling Agents | 1 | 2009 | 15 | 0.180 |
Why?
|
| Hypogonadism | 1 | 2009 | 21 | 0.170 |
Why?
|
| Leiomyoma | 2 | 2010 | 26 | 0.170 |
Why?
|
| Uterine Neoplasms | 2 | 2010 | 36 | 0.170 |
Why?
|
| Hydroxyurea | 1 | 2009 | 34 | 0.170 |
Why?
|
| Milk Banks | 1 | 2018 | 2 | 0.170 |
Why?
|
| Infertility, Male | 1 | 2009 | 44 | 0.170 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 446 | 0.170 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2018 | 39 | 0.170 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2018 | 35 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 2019 | 136 | 0.160 |
Why?
|
| Medicare | 1 | 2019 | 188 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 142 | 0.160 |
Why?
|
| Chemotactic Factors | 1 | 2007 | 7 | 0.160 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 15 | 0.150 |
Why?
|
| HIV-1 | 1 | 2022 | 678 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2009 | 169 | 0.150 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 207 | 0.150 |
Why?
|
| Chemokines | 1 | 2007 | 89 | 0.150 |
Why?
|
| Carcinoma | 1 | 2007 | 94 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2010 | 1149 | 0.140 |
Why?
|
| Infant | 1 | 2018 | 1014 | 0.130 |
Why?
|
| Healthy People Programs | 1 | 2005 | 22 | 0.130 |
Why?
|
| Public Health Administration | 1 | 2005 | 25 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 55 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2005 | 159 | 0.120 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2002 | 21 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2002 | 89 | 0.110 |
Why?
|
| Accreditation | 1 | 2012 | 18 | 0.110 |
Why?
|
| Georgia | 1 | 2012 | 155 | 0.100 |
Why?
|
| Middle Aged | 6 | 2007 | 9642 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2012 | 121 | 0.090 |
Why?
|
| Animals | 7 | 2018 | 14307 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 65 | 0.090 |
Why?
|
| HIV Infections | 1 | 2022 | 2207 | 0.080 |
Why?
|
| Vulnerable Populations | 1 | 2009 | 132 | 0.080 |
Why?
|
| Male | 4 | 2021 | 18870 | 0.080 |
Why?
|
| Health Personnel | 1 | 2009 | 200 | 0.080 |
Why?
|
| Depsipeptides | 1 | 2007 | 7 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2012 | 371 | 0.080 |
Why?
|
| Cystitis | 1 | 2007 | 6 | 0.080 |
Why?
|
| Urinary Tract Infections | 1 | 2007 | 36 | 0.070 |
Why?
|
| Osteocalcin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Escherichia coli Infections | 1 | 2007 | 39 | 0.070 |
Why?
|
| Histone Deacetylases | 1 | 2007 | 52 | 0.070 |
Why?
|
| Antioxidants | 1 | 2010 | 386 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2007 | 143 | 0.070 |
Why?
|
| Female Urogenital Diseases | 1 | 2005 | 2 | 0.070 |
Why?
|
| Social Justice | 2 | 2011 | 53 | 0.070 |
Why?
|
| Hormone Replacement Therapy | 1 | 2006 | 41 | 0.070 |
Why?
|
| Pituitary-Adrenal System | 1 | 2005 | 36 | 0.070 |
Why?
|
| Bone and Bones | 1 | 2006 | 89 | 0.070 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2005 | 49 | 0.070 |
Why?
|
| Apoptosis | 2 | 2010 | 1317 | 0.070 |
Why?
|
| Urogenital System | 1 | 2005 | 2 | 0.070 |
Why?
|
| Vasomotor System | 1 | 2005 | 3 | 0.070 |
Why?
|
| Mice | 5 | 2010 | 5668 | 0.070 |
Why?
|
| Ovarian Follicle | 1 | 2005 | 31 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2005 | 42 | 0.060 |
Why?
|
| Atrophy | 1 | 2005 | 40 | 0.060 |
Why?
|
| Aged | 4 | 2007 | 6448 | 0.060 |
Why?
|
| Reproduction | 1 | 2005 | 63 | 0.060 |
Why?
|
| Plant Extracts | 2 | 2022 | 250 | 0.060 |
Why?
|
| Lipids | 1 | 2006 | 222 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 1003 | 0.060 |
Why?
|
| Body Weight | 1 | 2006 | 404 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2004 | 65 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2010 | 480 | 0.060 |
Why?
|
| Estradiol Congeners | 1 | 2002 | 1 | 0.060 |
Why?
|
| Progesterone Congeners | 1 | 2002 | 2 | 0.060 |
Why?
|
| Uterine Hemorrhage | 1 | 2002 | 14 | 0.050 |
Why?
|
| Danazol | 1 | 2002 | 3 | 0.050 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2002 | 7 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2002 | 29 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2006 | 1422 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2006 | 1353 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2002 | 38 | 0.050 |
Why?
|
| Recurrence | 1 | 2002 | 125 | 0.050 |
Why?
|
| Endometrium | 1 | 2002 | 57 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2022 | 148 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 233 | 0.050 |
Why?
|
| Adult | 3 | 2007 | 11034 | 0.050 |
Why?
|
| Quality of Life | 1 | 2005 | 459 | 0.050 |
Why?
|
| Embryo Research | 1 | 2010 | 2 | 0.050 |
Why?
|
| Ovarian Hyperstimulation Syndrome | 1 | 2010 | 2 | 0.050 |
Why?
|
| Health Services Research | 1 | 2011 | 133 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2010 | 6 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2010 | 42 | 0.050 |
Why?
|
| Communicable Diseases | 1 | 2010 | 42 | 0.040 |
Why?
|
| Depression | 1 | 2005 | 664 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2009 | 38 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 121 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 187 | 0.040 |
Why?
|
| Research Design | 1 | 2010 | 292 | 0.040 |
Why?
|
| Testis | 1 | 2009 | 185 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2007 | 33 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 608 | 0.040 |
Why?
|
| Mass Screening | 1 | 2010 | 427 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 298 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 200 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 254 | 0.030 |
Why?
|
| Boston | 1 | 2005 | 20 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2009 | 1802 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 325 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2005 | 35 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2007 | 306 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 118 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 1300 | 0.030 |
Why?
|
| Decision Making | 1 | 2005 | 189 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 248 | 0.030 |
Why?
|
| Camellia sinensis | 1 | 2009 | 1 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 3414 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2009 | 72 | 0.020 |
Why?
|
| Models, Educational | 1 | 2009 | 41 | 0.020 |
Why?
|
| Tea | 1 | 2009 | 41 | 0.020 |
Why?
|
| Health Care Reform | 1 | 2009 | 31 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 323 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 139 | 0.020 |
Why?
|
| Prejudice | 1 | 2009 | 101 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2009 | 210 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2007 | 21 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 11 | 0.020 |
Why?
|
| Histone Deacetylase 1 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Fimbriae Proteins | 1 | 2007 | 18 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2007 | 83 | 0.020 |
Why?
|
| Butyrates | 1 | 2007 | 31 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 30 | 0.020 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 33 | 0.020 |
Why?
|
| Acetylation | 1 | 2007 | 94 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 41 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2007 | 104 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 984 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 92 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 160 | 0.020 |
Why?
|
| Anovulation | 1 | 2005 | 4 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2005 | 13 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2005 | 45 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2005 | 62 | 0.020 |
Why?
|
| Estrous Cycle | 1 | 2005 | 34 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 41 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 396 | 0.020 |
Why?
|
| Time Factors | 1 | 2009 | 1681 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 391 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 834 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 580 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 550 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 1426 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2007 | 436 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 605 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 897 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1152 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 1530 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 1503 | 0.010 |
Why?
|
Montgomery Rice's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(198)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(16)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_